Fentanyl’s Medical Origins
The history of fentanyl connects a pharmaceutical development with later, profoundly different patterns of production and supply. Fentanyl emerged from Paul Janssen’s pharmaceutical research in Belgium around the turn of the 1960s. Researchers were studying synthetic compounds related to existing opioid pain medicines. A historical review by Theodore Stanley and colleagues identifies 1960 as the breakthrough year for fentanyl’s synthesis, while other accounts place initial development in 1959. The safest broad description is the late 1950s and early 1960s.12
This was a medical research programme, not a substance originally invented for the illicit market. Fentanyl’s potency and rapid action made it relevant to anaesthesia and pain treatment, where the effect of a medicine can be controlled and observed. That clinical origin is essential to understanding why the drug became established before its later public-health significance.1
Entry into medical practice
Fentanyl entered United States medical use in 1968. Early applications were closely connected to anaesthesia, including use alongside other medicines. Subsequent research developed related compounds with different clinical characteristics. The history therefore concerns a family of medical developments as well as one chemical name.23
Over time, pharmaceutical formulations expanded beyond the original surgical setting. These changes responded to particular clinical needs and regulatory decisions. They should not be interpreted as making all fentanyl products interchangeable. A historical account can describe that expansion without giving instructions about administration, dose, or substitution.
A separate supply chain
Illicitly manufactured fentanyl belongs to a different production and distribution history from regulated pharmaceutical products. The United States experienced earlier episodes involving illicit fentanyl and related substances, but the expansion of synthetic opioids in the illicit drug supply became a defining development of the 2010s.34
The distinction matters because a single word can obscure different contexts: a medicine manufactured under regulation, a diverted pharmaceutical product, an illicitly produced substance, or a counterfeit tablet containing it. Public-health reporting increasingly separates these pathways. It is inaccurate to explain the modern crisis simply as the direct continuation of hospital use.
Why the history changed
Synthetic production altered the economics and geography of opioid supply. A highly potent substance can be distributed in small quantities, and illicit markets do not offer the composition controls associated with regulated medicines. Counterfeit products and mixtures made the uncertainty of exposure part of the historical problem.4
The resulting history has two connected but distinct threads: an important development in twentieth-century pharmacology, and a major public-health emergency linked to illicit supply. Keeping both in view avoids two misleading extremes—treating every medical use as equivalent to illicit exposure, or assuming a medicine’s legitimate origin makes an unregulated product predictable. The historical question is how institutions, markets, and uses changed around the same substance.
The story at a glance
Fentanyl Timeline
Follow the evidence
Sources & further reading
Numbered links in the text point to these sources. Dates and interpretations are identified as approximate or disputed where the evidence requires it.